Provided by Tiger Trade Technology Pte. Ltd.

Gilead Sciences

145.14
-3.0800-2.08%
Post-market: 148.223.08+2.12%19:55 EST
Volume:6.94M
Turnover:1.01B
Market Cap:180.07B
PE:21.41
High:146.75
Open:146.32
Low:143.35
Close:148.22
52wk High:157.29
52wk Low:93.37
Shares:1.24B
Float Shares:1.24B
Volume Ratio:0.88
T/O Rate:0.56%
Dividend:3.16
Dividend Rate:2.18%
EPS(TTM):6.78
EPS(LYR):6.78
ROE:40.66%
ROA:12.52%
PB:7.93
PE(LYR):21.41

Loading ...

Gilead Sciences Inc. Stock Outperforms Competitors Despite Losses On The Day

Dow Jones
·
5 hours ago

Gilead Sciences to Buy Arcellx for $115 a Share Plus $5 CVR

Reuters
·
8 hours ago

Tango Therapeutics posts FY 2025 collaboration revenue of USD 62.4 million +108.2%

Reuters
·
Yesterday

South Africa seeks local production of Gilead's HIV prevention drug

Reuters
·
Yesterday

Gilead Sciences Inc. Stock Underperforms Tuesday When Compared To Competitors

Dow Jones
·
Mar 04

Gilead Exec Says Anito-Cel Could Address an "up to $20 Billion" Multiple Myeloma Opportunity When Considering Use in First-Line Treatment- TD Cowen Conference

THOMSON REUTERS
·
Mar 04

Gilead Exec Says Anito-Cel Is Expected to Launch at the End of This Year - TD Cowen Conference

THOMSON REUTERS
·
Mar 04

Gilead Sciences CEO Daniel Patrick O'Day Disposes of Common Shares

Reuters
·
Mar 03

BRIEF-Gilead Foundation Awards $12 Million To Empower Community Health Workers And Expand Hiv Prevention Initiatives Across 14 States And The District Of Columbia

Reuters
·
Mar 02

Gilead Foundation Awards $12 Million to Empower Community Health Workers and Expand Hiv Prevention Initiatives Across 14 States and the District of Columbia

THOMSON REUTERS
·
Mar 02

CORRECTED-Israel's Compugen Q4 revenue beats on rilvegostomig royalties

Reuters
·
Mar 02

Compugen Ltd. Publishes Corporate Presentation on AI-Driven Immuno-Oncology Antibody Pipeline

Reuters
·
Mar 02

Compugen posts FY 2025 revenue of USD 72.8 million (+161.0%)

Reuters
·
Mar 02

United Therapeutics' drug slows progression of rare lung condition in late-stage study

Reuters
·
Mar 02

Gilead Sciences Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Feb 28

Gilead Sciences Inc Stock Moved Up by 3.72% on Feb 27: What Investors Need To Know

TradingKey
·
Feb 28

Arcellx FY 2025 collaboration revenue falls 79% to USD 22.3 million

Reuters
·
Feb 27

Gilead Sciences: Advancing Long-Acting HIV Franchise Underscores Competitive Edge and Supports Buy Rating

TIPRANKS
·
Feb 26

Gilead Says HIV Treatment Trial Results Show Efficacy

Dow Jones
·
Feb 26

Gilead presents new Phase 3 ARTISTRY-1 and ARTISTRY-2 trial data

TIPRANKS
·
Feb 26